Stat3 Therapeutics, Inc.

stat3 therapeutics is a pre-clinical, oncology company dedicated to developing and commercializing drugs that target the activated stat3 molecule. our unique approach arrests the activity of the stat3 dimer using a cyclic decoy that binds to the molecule in a way that is both specific and impactful without significant toxic side effects. stat3 activation increases cancer cell proliferation, promotes immunosuppression, and appears in over 70% of all human cancers. stat3 plays an important regulatory role in a variety of cancers and also has been indicated as a factor in non-cancer indications such as autoimmune diseases. with this in mind, stat3 therapeutics approach to drug development has broad applicability. our initial focus on head and neck cancers where 95% of all such cancers shows hyperactivated stat3 present.